Qure.ai's Aira wins Class IIb CE mark for emerging-market AI care

Qure.ai, the Mumbai- and New York-headquartered AI diagnostics company, has secured Class IIb certification under the EU Medical Device Regulation (MDR) for Aira, its AI-powered clinical decision support system (CDSS). The classification sits at one of the EU regulatory framework's most stringent tiers for software whose outputs directly influence patient care decisions. For health ministries, institutional funders and procurement bodies evaluating AI tools at scale, it provides an independently assessed baseline, a signal that matters as much in Lagos or Nairobi as in Lisbon.

Aira is designed not for hospital radiology suites in high-income markets but for the overstretched frontline worker in a last-mile clinic in Nigeria or a peri-urban health post in Bangladesh. The platform integrates as an AI layer on top of existing health systems, converting paper records and verbal consultations into structured digital care trails, surfacing national guideline-based recommendations and automating patient follow-up, including reminder calls in local languages such as Hausa. The company says the system is designed to run on existing digital devices and tolerate unreliable connectivity, making digitisation an embedded part of care delivery rather than an additional administrative burden.

From pilots to population scale

In its first year since launching at the World Health Assembly in 2025, Aira has reached thousands of patients across ten live pilot sites spanning Nigeria, Kenya, Mozambique, the Solomon Islands and Bangladesh. The company reports that in a Kenya outreach programme, Aira reduced time spent on protocol-driven documentation by 32% while achieving a 98% completion rate on those tasks. In Nigerian HIV primary care facilities, the ratio of clinical to administrative time improved by 67% in favour of patient-facing work, alongside a 23% reduction in administrative time overall.

Partners on the ground include the Catholic Caritas Foundation of Nigeria, the Adamawa State HIV/AIDS and STI Control Program, Kenya's Ministry of Health, and VillageReach in Mozambique, where Aira is integrated into the national AlôVida platform with support from a Gates Foundation-backed pandemic preparedness initiative. The geographic spread, from West Africa to the Pacific Islands, is deliberate; Qure.ai says it is building an evidence base for population-scale AI-supported care that can be presented to ministries and institutional funders with real-world performance data rather than modelled projections.

"The quality of primary care a person receives should not be decided by their postcode," said Prashant Warier, co-founder and CEO of Qure.ai. "Class IIb certification is an important milestone because it validates our clinical decision support within one of the world's most rigorous medical device regulatory frameworks."

The convergence play: regulatory infrastructure meets capital allocation

The Class IIb designation matters beyond Qure.ai itself. As AI health tools proliferate across emerging markets, the absence of regulatory anchors has slowed institutional procurement, health ministries and multilateral funders have lacked a common evidentiary standard against which to evaluate competing platforms. EU MDR Class IIb accreditation, applied to a tool built specifically for low-resource settings, begins to close that gap. It positions CE marking as a de facto international quality benchmark in markets where domestic regulatory capacity remains thin.

For cross-sector capital allocators, this signals a maturing market. Global health-focused investors, from development finance institutions such as the IFC and the British International Investment arm to impact-oriented venture funds, have long been wary of backing AI health tools that cannot clear a major regulatory hurdle. A CE mark at Class IIb level changes the risk calculus, potentially accelerating capital flows into AI-enabled primary care infrastructure across Sub-Saharan Africa and South and Southeast Asia.

Qure.ai's broader portfolio already spans 105-plus countries with more than 26 FDA-cleared findings and CE marking across 60-plus clinical indications. The company's next frontier is population-scale deployment of Aira over national health systems, a move that would test whether AI clinical decision support can function as sovereign health infrastructure, not merely a pilot programme. If it can, the model could inform how multilateral bodies such as the WHO and the Gates Foundation structure future AI health investment across the Global South.